Clinical Trial

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Current anti-diabetic treatment fails to stop the progressive course of the disease. Recent studies have revealed a surprisingly high variability in the diabetic phenotype. The investigators propose that anti-diabetic treatment should ideally target the underlying pathophysiology of each individual patient. The investigators will therefore test whether the effect of two approved anti-diabetic drugs differs between individuals at different ends of the pathophysiological spectrum: 1) patients with poor insulin secretion, here termed SIDD and 2) patients with high insulin resistance, here termed SIRD. The study may open up a new avenue for more precise treatment of diabetic patients that would be of immediate clinical relevance.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-06-25; most recent amendment 2025-07-13.
Status change: Recruiting → Active, Not Recruiting 2021-09-21
Trial Details
NCT Number NCT04451837
Lead Sponsor Region Skane
Collaborators: Göteborg University
Conditions Type2 Diabetes
Enrollment 200 participants
Start Date 2020-09-10
Primary Completion 2021-12-15 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-16